SLG
ADAP

Stanley-Laman Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Stanley-Laman Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-565,271
Closed -$7.67M – 250
2018
Q3 		$7.67M Buy
+565,271
New +$5.93M 1.88% 5

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stanley-Laman Group's ADAP Position: Q4 2018 in Review

Stanley-Laman Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2018, closing a stake of 565,271 shares — an estimated $7.67M sold.

Stanley-Laman Group first reported a position in ADAP in Q3 2018 and held it in 1 quarter. The position peaked at $7.67M in Q3 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2018.

  • Stanley-Laman Group reported no remaining Adaptimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 565,271 Adaptimmune Therapeutics shares in Q4 2018, an estimated $7.67M.
  • Stanley-Laman Group first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Adaptimmune Therapeutics position peaked at $7.67M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.